VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005914/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia in the People’s Republic of China. Under the agreement, Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China.
Stefan Schulze, CEO of Vifor Pharma Group comments, “We are delighted to expand VFMCRP’s collaboration with Fresenius Kabi. There is a high prevalence of CKD and heart failure in China3 and hyperkalemia is one of the most common complications associated with these two conditions. As a result there is a high demand for an effective, proven hyperkalemia treatment. The excellent commercial infrastructure, the well established relationships in nephrology and our existing successful collaboration make Fresenius Kabi our partner of choice to provide Veltassa® to patients.”
Oskar Haszonits, President Region Asia Pacific of Fresenius Kabi said, “This agreement is an important step in intensifying our collaboration and relationship with VFMCRP in nephrology. We believe Veltassa® has the potential to provide many benefits to patients across the country, and we look forward to adding it to our portfolio and working with VFMCRP.”
Hyperkalemia is a serious medical condition characterized by elevated levels of potassium in the blood and can be associated with life-threatening consequences. Patients with CKD and heart failure, especially those treated with RAAS (renin-angiotensin-aldosterone system) inhibitors are at particular risk of developing hyperkalemia. As a consequence, RAASi therapy, the cornerstone of treatment for CKD and heart failure, is often reduced or discontinued, compromising cardio-renal protection. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.
Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In China, the company is among the top 10 multinational pharmaceutical companies, being a market leader in clinical nutrition, anesthesia and nephrology. Fresenius Kabi has around 6,000 employees in China.
Both parties have agreed to not disclose financial terms of the collaboration.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.
Approximately 73% of advanced Chronic Kidney Disease (CKD) and 40% of chronic heart failure patients may be at risk of elevated blood potassium levels4. Hyperkalemia can cause abnormal heart rhythms and even sudden death5. There are often no warning signs, meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events. Some medicines that are often prescribed to people with CKD and heart failure to help delay progression of their underlying disease and reduce mortality can cause hyperkalemia as a side effect. These may include RAASi such as angiotensin receptor blockers (ARBs), aldosterone antagonists (AAs) and angiotensin converting-enzyme (ACE) inhibitors as well as angiotensin II receptor/neprilysin inhibitors (ARNI).
Veltassa® is a potassium binder approved for the treatment of hyperkalemia. Veltassa® was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium.Veltassa® should not replace emergency treatment for life-threatening hyperkalemia. Made in powder form, Veltassa® is mixed with water and taken once a day with or without food. Veltassa® is consisting of smooth, spherical, uniform microbeads too large to be absorbed, thus protecting the gastrointestinal tract. Veltassa® works primarily in the lumen of the colon where potassium concentration is highest, and the residence time of the polymer is the longest. The potassium is then excreted from the body through the normal excretion process.
1 Veltassa® EU SmPC 2019
2 Agarwal R, et al. Lancet 2019;394:1540–50.
3 Zhang et al. Lancet. 2012 Mar 3;379(9818):815-22; Guo et al. Int J Environ Res Public Health 2016; 13: E770. Guo et al. Curr Cardiol Rev. 2013 May; 9(2): 112–122.
4 Rosano GCM, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2018;4:180-188.
5 Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77:759-764.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Global Head Corporate Communications
+41 79 957 96 73
Head of Investor Relations
+41 58 851 66 90
Fresenius SE & Co. KGaA
61352 Bad Homburg, Germany
+49 6172 60 82 115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Banks Preparing to Leverage SWIFT’s New Platform for International Payments Flows24.6.2021 10:00:00 EEST | Press release
Six leading global banks today announced their endorsement for SWIFT’s new transaction management platform and are preparing to use its expanded capabilities to enable new services, improve efficiency and reduce costs when the platform goes live in November 2022. Bank of China, Bank of New York Mellon, BNP Paribas, Citi, Deutsche Bank, and Standard Chartered confirmed their preparations for the platform as the co-operative detailed an ambitious roadmap it will roll out over the next 18 months. New features – including upfront validation of beneficiary details, central management of exceptions, extension of SWIFT’s high-speed gpi rails to lower-value payments and new rich data services based on the ISO 20022 standard – will serve as the building blocks of the enhanced platform. These are integral components of SWIFT’s strategy to facilitate instant and frictionless end-to-end transactions anywhere in the world. The platform evolution builds on extensive work by the SWIFT community in th
ADVA makes virtual routing simple and affordable with Ensemble SmartWAN24.6.2021 10:00:00 EEST | Press release
ADVA (FSE: ADV) today launched its fully featured Ensemble SmartWAN secure networking solution. Integrated into ADVA’s Ensemble network functions virtualization (NFV) suite, the new technology offers enterprises a simple and affordable way to leverage the core benefits of software-defined WAN (SD-WAN), while removing the need for additional virtual network functions (VNFs). Now businesses can deploy a turnkey solution that delivers dynamic virtual routing, centralized management, and full visibility of network topology. With zero-touch provisioning for easy deployment and temperature-hardened servers, Ensemble SmartWAN significantly improves return on investment for applications such as dynamic and fully meshed networking and smart city services. At the same time, it preserves the benefits of an open system that supports runtime additions of new VNFs or user applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624
HIGH VIEW Renews Contract with SES, DELUXE MUSIC Airs via ASTRA 19.2 degrees East24.6.2021 09:50:00 EEST | Press release
HIGH VIEW, an independent Munich-based media company, has extended its partnership with SES in a new multi-year contract and secured long-term satellite capacity. Its DELUXE MUSIC channel will continue broadcasting on SES’s satellites in SD and HD quality at its prime TV neighbourhood at ASTRA 19.2 degrees East. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623006029/en/ HIGH VIEW Renews Contract with SES, DELUXE MUSIC Airs via ASTRA 19.2 degrees East (Photo: Business Wire) Reaching up to four million viewers a day, DELUXE MUSIC delivers a mix of current hits, classics and exciting new trends on 20 different editorially-curated shows and moderated programs. With this multi-year contract, viewers in the region will continue to enjoy free-to-air DELUXE MUSIC in SD, and in HD via SES’s leading TV platform in Germany – HD+. "Our focus is on delivering extraordinary music experiences to our viewers, so we are pleased that we
Visa To Acquire European Open Banking Platform Tink24.6.2021 09:45:00 EEST | Press release
Visa (NYSE: V) today announced it has signed a definitive agreement to acquire Tink, a European open banking platform that enables financial institutions, fintechs and merchants to build tailored financial management tools, products and services for European consumers and businesses based on their financial data. Visa will pay total financial consideration of 1.8 billion Euros, inclusive of cash and retention incentives, to acquire Tink. Through a single API, Tink allows its customers to access aggregated financial data, use smart financial services such as risk insights and account verification and build personal finance management tools. Tink is integrated with more than 3,400 banks and financial institutions, reaching millions of bank customers across Europe. Tink will retain its brand and current management team, and its headquarters will remain in Stockholm, Sweden. The combination of Visa’s proven infrastructure and sustained investment in resilience, cybersecurity and fraud prev
Pharmsynthez PJSC Secures RUB 800m With LDA Capital24.6.2021 08:00:00 EEST | Press release
Innovative Russian pharmaceutical developer, Pharmsynthez PJSC (MOEX:LIFE), and global alternative investment group, LDA Capital, enter into a Put Option Agreement for 800 million rubles to help finance the development of Pharmsynthez’s pioneering projects over the next 36 months, including those aimed at combating COVID-19. Both Pharmsynthez and LDA view this capital allocation not only as an investment into the Company but also as a starting point for a long-term strategic partnership to advance Pharmsynthez’s promising projects in the field of innovative pharmaceutical technologies and development of the latest treatments for complex diseases. LDA Capital’s investments will accelerate Pharmsynthez PJSC projects in all aspects. The Company’s business plan until 2025 allows for the introduction of several highly profitable original drugs (Epolong® and other finished dosage forms) to the domestic market, an increase in the production of active pharmaceutical ingredients, and the launch
Global Consumer Brands Unveil World’s First Enzymatically Recycled Bottles24.6.2021 08:00:00 EEST | Press release
The promise of endlessly recycled PET plastic is one step closer today, as the Consortium – Carbios, L’Oréal, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe – announces the successful production of the world’s first food-grade PET plastic bottles produced entirely from enzymatically recycled plastic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005867/en/ Closing the loop for recycling PET plastic. Photo credit: Jérôme Pallé (Photo: Business Wire) Each Consortium company has successfully manufactured sample bottles – based on Carbios’ enzymatic PET recycling technology – for some of their leading products including: Biotherm®, Perrier®, Pepsi Max®** and Orangina®. Today’s announcement is the culmination of nearly 10 years’ research and development by Carbios to create a new process and supercharge an enzyme naturally occurring in compost heaps that normally breaks down leaf membranes of dead plants. By ada
Vifor Pharma to revise DIAMOND study, readout expected in H2 202124.6.2021 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in potassium management in high-risk heart failure patients treated with guideline-recommended doses of renin-angiotensin aldosterone system inhibitor (RAASi). This decision has been made on the recommendation from the independent study Executive Committee and following the significant impact of COVID-19 on recruitment. Patients with heart failure and chronic kidney disease are among those at the highest risk of severe outcomes of COVID-19 infection. During the pandemic, treatment practices have been adapted to reduce risks of exposure to COVID-19 during hospital visits, disrupting clinical care and impacting the conduct of randomized clinical trials such as the DIAMOND study. This has led to fewer patients enrolled in the trial than anticipated and to a slower incidence of cardio-vascular events.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom